Overview

A Phase 3 Clinical Study of KHK 4827

Status:
Completed

Trial end date:
2016-07-04

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).

Phase:

Phase 3

Details

Lead Sponsor:

Kyowa Hakko Kirin Company, Limited
Kyowa Kirin Co., Ltd.

Treatments:

Brodalumab